Are there still other asbestos-related malignancies to be discovered?

1.Ortonne N: Update on cutaneous lymphomas. Diagnostic histopathology 2018;24:301-12.10.1016/j.mpdhp.2018.06.005Search in Google Scholar

2.Jawed SI, Myskowski PL, Horwitz S. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol 2014;70:205-e1.2443896910.1016/j.jaad.2013.07.04924438969Search in Google Scholar

3. Beyer M, Möbs M, Humme D, Sterry W. Pathogenese der Mycosis fungoides. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2011;9:594-9.10.1111/j.1610-0387.2011.07635_suppl.xSearch in Google Scholar

4.A. Kelati et al, Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis, International Journal of Women’s Dermatology, 2017, vol 3(2): 100-106.10.1016/j.ijwd.2016.11.006544045328560304Search in Google Scholar

5.Kelati A, Gallouj S, Tahiri L. Defining the mimics and clinicohistological diagnosis criteria for mycosis fungoides to minimize misdiagnosis. Int J Womens Health 2017;3:100-6.10.1016/j.ijwd.2016.11.006Search in Google Scholar

6.Willemze R, Meijer CJ.. Classification of cutaneous T-cell lymphoma: from Alibert to WHO-EORTC. J Cutan Pathol 2006;33:18–26.10.1111/j.0303-6987.2006.00494.x1641220916412209Open DOISearch in Google Scholar

7.Krejsgaard T, Odum N, Geisler C. Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome. Leukemia 2012;26:424.2190438510.1038/leu.2011.23721904385Search in Google Scholar

8.Saed G, Fivenson DP, Naidu Y. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile. J Invest Dermatol 1994; 103:29–33.10.1111/1523-1747.ep123889858027577Search in Google Scholar

9.Olek-Hrab K, Silny W. Diagnostics in mycosis fungoides and Sezary syndrome. Reports of Practical Oncology & Radiotherapy 2014;19:72-6.10.1016/j.rpor.2013.11.001405499024936324Search in Google Scholar

10.Al Hothali GI. Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach, Int J Health Sci (Qassim) 2013;7: 220–39.10.12816/0006045Search in Google Scholar

11.Morales-Suárez-Varela MM, Olsen J, Johansen P. Occupational risk factors for mycosis fungoides: a European multicenter case-control study, J Occup Environ Med.2004; 46:205-11.10.1097/01.jom.0000116819.01813.8c15091282Open DOISearch in Google Scholar

12.Slodownik D, Moshe S, Sprecher E. Occupational mycosis fungoides - a case series. Int J Dermatol 2017; 56:733-37.10.1111/ijd.1358928255994Open DOISearch in Google Scholar

13. Mortazavi H, Firouzabadi LI, Ghanadan A. Occurrence of Mycosis Fungoides in an Iranian Chemical Victim of the Iran-Iraq War with a Long-term Follow-Up: A Case Report and Review of Literature. Iran J Med Sci 2018;43:324.Search in Google Scholar

14.Bianchi C, Bianchi T. Non-Hodgkin lymphoma and pleural mesothelioma in a person exposed to asbestos. Turk Patoloji Derg. 2018;34:190-3.Search in Google Scholar

15.Chirinos R, Geskin L. Coexistence of mycosis fungoides and malignant mesothelioma in two patients from the same geographic area. J Am Acad Dermatol 2008;58:suppl2:AB77.10.1016/j.jaad.2007.10.344Search in Google Scholar

16.IARC Monographs on the Evalation of Carcinogenic risks to Human. Handbooks of Cancer Prevention. Available: https://monographs.iarc.fr [Accessed on 12.10.2018].Search in Google Scholar

17.Matsuzaki H, Maeda Megumi, Suni Lee. Asbestos-Induced Cellular and Molecular Alteration of Immunocompetent Cells and Their Relationship with Chronic Inflammation and Carcinogenesis. J Biomed Biotechnol 2012:9.10.1155/2012/492608Search in Google Scholar

18.Naofumi Hara, Nobukazu Fujimoto, Yosuke Miyamoto. Lymphoproliferative disorder in pleural effusion in a subject with past asbestos exposure. Respir Med Case Rep 2015; 16:169-71.10.1016/j.rmcr.2015.11.002Search in Google Scholar

19.Agency for Toxic Substances and Disease Registry. Toxicological Profile for Asbestos. Atlanta, GA: Agency for Toxic Substances and Disease Registry; 2001. Available: http://www.atsdr.cdc.gov/toxprofiles/tp61.html [Accessed on 15.11.2018].Search in Google Scholar

20.Naghi E, Rascu A. Pneumoconioze, in Pneumologie, sub redactia Miron Alexandru Bogdan Ed.Universitara “Carol Davila”, Bucuresti, 2008, 291-303.Search in Google Scholar

21.Maeda M, Nishimura Y, Kumagai N. Dysregulation of the immune system caused by silica and asbestos. J Immunotoxicol 2010;7:268-78.10.3109/1547691X.2010.512579Open DOISearch in Google Scholar

22.Nisimura Y, Kumagai-Takei N, Matsuzaki H. Functional Alteration of Natural Killer Cells and Cytotoxic T Lymphocytes upon Asbestos Exposure and in Malignant Mesothelioma Patients. Biomed Res Int 2015;2015:238431.10.1155/2015/238431Search in Google Scholar

23. Kumagai-Takei N, Nishimura Y, Maeda M. Functional Properties of CD8. J Immunol Res. 2014;2014.10.1155/2014/670140Search in Google Scholar

24.Becker N, Berger J, Bolm-Audorff U. Asbestos exposure and malignant lymphomas-a review of the epidemiological literature. Int Arch Occup Environ Health 2001;74:459-69).10.1007/s004200100253Open DOISearch in Google Scholar

25.Tan RS, Butterworth, McLaughlin H. Mycosis fungoides - a disease of antigen persistence. Br J Dermatol. 1974;91:607-16.10.1111/j.1365-2133.1974.tb12449.xOpen DOISearch in Google Scholar

26.Stadler R, Stranzenbach R. Molecular pathogenesis of cutaneous lymphomas. Exp. Dermatol 2018;27:1078-83.10.1111/exd.13701Search in Google Scholar

27.Lange A, Skibiński G, Garncarek D. The Follow-Up Study of Skin Reactivity to Recall Antigens and E- and EAC-RFC Profiles in Blood in Asbestos Workers. Immunobiology 1980:157:1-11.10.1016/S0171-2985(80)80056-8Search in Google Scholar

28.Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk 2012;12:291-6.10.1016/j.clml.2012.06.010347550823040434Search in Google Scholar